Zobrazeno 1 - 10
of 74
pro vyhledávání: '"M. Czuczman"'
Autor:
Turlough O’Hare, K Davis, Jaydeep Moro, Moin Khan, Mauricio Forero, Lehana Thabane, Thuva Vanniyasingam, Peter Moisiuk, Bashar Alolabi, Harsha Shanthanna, Gary Foster, M Czuczman
Publikováno v:
Anaesthesia. 77:301-310
Interscalene brachial plexus block is the standard regional analgesic technique for shoulder surgery. Given its adverse effects, alternative techniques have been explored. Reports suggest that the erector spinae plane block may potentially provide ef
Autor:
Cory Mavis, Natalie M Czuczman, Juan Gu, Song Liu, Francisco J. Hernandez-Ilizaliturri, Pavel Klener, Myron S. Czuczman, Qiang Hu, Sarah Frys, Petra Vockova, Matthew J. Barth, Vishala T. Neppalli
Publikováno v:
Blood. 127:1128-1137
Mantle cell lymphoma (MCL) is characterized by an aggressive clinical course and inevitable development of refractory disease, stressing the need to develop alternative therapeutic strategies. To this end, we evaluated pevonedistat (MLN4924), a novel
Autor:
Nathan Fowler, Huilai Zhang, Koji Izutsu, Stacey Kalambakas, Catherine Thieblemont, Phillip Scheinberg, Ian W. Flinn, Xiaonan Hong, John P. Leonard, Francesca Re, Cláudia Moreira, John G. Gribben, Marek Trneny, G.S. Nowakowski, Pierre Fustier, Antonello Pinto, F. Offner, M. Czuczman, Laura Fogliatto, Adriana Scheliga, Chengqing Wu
Publikováno v:
HemaSphere. 3:577-578
Autor:
John F. Gibbs, Ritesh Patil, Myron S. Czuczman, Cory Mavis, Juan J Gu, George Deeb, Francisco J. Hernandez-Ilizaliturri, Natalie M Czuczman, Joseph J. Skitzki
Publikováno v:
Anti-Cancer Drugs. 24:1030-1038
To further develop therapeutic strategies targeting the proteasome system, we studied the antitumor activity and mechanisms of action of MLN2238, a reversible proteasome inhibitor, in preclinical lymphoma models. Experiments were conducted in rituxim
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Myron S. Czuczman, Juan J Gu, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Gregory P. Kaufman, Joseph J. Skitzki, Natalie M Czuczman
Targeting the proteasome system with bortezomib (BTZ) results in anti-tumour activity and potentiates the effects of chemotherapy/biological agents in multiple myeloma and B-cell lymphoma. Carfilzomib (CFZ) is a more selective proteasome inhibitor th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e364bdec6a57f44083211be0d47c05f2
https://europepmc.org/articles/PMC3760501/
https://europepmc.org/articles/PMC3760501/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sarah Frys, Cory Mavis, Rodney R. Miles, Matthew J. Barth, Aradhana Awasthi Tiwari, Natalie M Czuczman, Megan S. Lim, Delphine Rolland, Mitchell S. Cairo
Publikováno v:
Blood. 124:1769-1769
Multi-agent chemotherapy regimens have significantly improved long-term survival of pediatric Burkitt Lymphoma (BL) to over 80%. However, patients with refractory or relapsed disease have a dismal prognosis, stressing the need to identify mechanisms
Autor:
P. Gilman, A. Lowe, Michael L. Grossbard, Julie M. Vose, M. Czuczman, L. A. Kunkel, R. I. Fisher, A. Grillo-Lopez, Brian K. Link
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(2)
PURPOSE: To determine the safety and efficacy of the combination of the chimeric anti-CD20 antibody Rituxan (rituximab, IDEC-C2B8; Genentech Inc, South San Francisco, CA) and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemother
Autor:
Matthew J. Barth, Natalie M Czuczman, Cory Mavis, Myron S. Czuczman, Sarah Frys, Francisco J. Hernandez-Ilizaliturri, Pavel Klener
Publikováno v:
Blood. 122:647-647
MCL is characterized by an aggressive clinical course and inevitable development of refractory disease despite early interventions that include immunotherapy (i.e. rituximab), multi-agent induction chemotherapy (that contains high-dose cytarabine or